Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures
View Patent ↗Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.
1. A locally deliverable composition for inhibiting pain/inflammation and spasm, comprising a combination of ketoprofen and nifedipine and at least one stabilizing agent in a liquid solvent irrigation carrier, each of the ketoprofen and the nifedipine included in a therapeutically effective amount such that the combination inhibits pain/inflammation and spasm at a site of local delivery, wherein the ketoprofen is included at a concentration of no more than 500,000 nanomolar, the nifedipine is included at a concentration of no more than 200,000 nanomolar, the at least one stabilizing agent comprises propyl gallate and the composition further comprises sodium metabisulfite.
2. The composition of claim 1 , wherein ketoprofen comprises the S-(+)-enantiomer, dexketoprofen.
3. The composition of claim 1 , wherein the solvent comprises an aqueous solvent.
4. The composition of claim 1 , wherein the composition further comprises polyethylene glycol 400 as a cosolvent.
5. The composition of claim 4 , wherein the composition further comprises a citric acid buffer.
6. The composition of claim 1 , wherein the composition further comprises a buffer.
7. The composition of claim 6 , wherein the buffer comprises a citric acid buffer.
8. The composition of claim 3 , wherein the composition further comprises a cosolvent.
9. The composition of claim 8 , wherein the cosolvent comprises polyethylene glycol.
10. The composition of claim 9 , wherein the cosolvent comprises polyethylene glycol 400.
11. The composition of claim 8 , wherein the composition further comprises propyl gallate.
12. The composition of claim 3 , wherein the composition further comprises a buffer.
13. The composition of claim 12 , wherein the buffer comprises a citric acid buffer.
14. The composition of claim 1 , wherein the ketoprofen is included at a concentration of no more than 300,000 nanomolar and the nifedipine is included at a concentration of no more than 100,000 nanomolar.
15. The composition of claim 1 , wherein the ketoprofen and nifedipine are included at a ketoprofen to nifedipine molar ratio of between 10:1 to 1:10.
16. The composition of claim 15 , wherein the ketoprofen and nifedipine are included at a ketoprofen to nifedipine molar ratio of between 5:1 to 1:5.
17. The composition of claim 16 , wherein the ketoprofen and nifedipine are included at a ketoprofen to nifedipine molar ratio of between 4:1 to 1:1.
18. The composition of claim 17 , wherein the ketoprofen and nifedipine are included at a ketoprofen to nifedipine molar ratio of 3:1 plus or minus 20%.